<DOC>
	<DOCNO>NCT02470299</DOCNO>
	<brief_summary>There move towards personalized medicine cancer care , significant effort underway evaluate new target therapeutic treatment ovarian cancer . One way identify potential new drug target screen drug library determine whether drug library target key kinase enzymatic site cellular signal pathway . Previous preclinical work pilot study demonstrate ketorolac ( type non-steroidal anti-inflammatory drug ) inhibit GTPase activity ovarian cancer cell retrieve post-operative peritoneal cavity . The purpose study confirm inhibitory effect ketorolac drive specific effect post-operative peritoneal compartment .</brief_summary>
	<brief_title>Evaluation GTPase Inhibition Post-operative Intravenous Ketorolac Ovarian Cancer Patients</brief_title>
	<detailed_description>Drug repurposing , screen library FDA approve agent , identify agent clinically available pharmacology pharmacokinetics know preclinical data generate rapidly without subsequent need GMP ( good manufacturing practice ) new drug production . Small GTPases , include member Rab , Ras Rho family , attractive target development cancer therapeutic base pivotal role protein traffic , proliferation/survival cytoskeletal organization , respectively . Ketorolac tromethamine non-steroidal anti-inflammatory drug identify previous in-silico drug screen inhibitor GTPases . In previous phase 0 clinical study , ketorolac administer intravenously ovarian cancer patient follow optimal cytoreductive surgery . Ovarian cancer cell obtain time surgery , prior ketorolac administration , various time ketorolac dose . Analysis GTPase activity specimens show time-dependent inhibition Rac1 Cdc42 GTPase activity . The purpose study confirm effect ketorolac drive specific effect post-operative peritoneal compartment .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Patients must suspect diagnosis ovarian , fallopian tube primary peritoneal cancer plan cytoreductive surgery . Borderline ovarian cancer ascites allowable . ECOG/Zubrod/SWOG Performance Status &lt; 2 ( Karnofsky Performance Status &gt; 70 % ) Female ' age ≥18 year Ability provide inform consent Baseline laboratory value ( bone marrow , renal , hepatic ) : Adequate bone marrow function : Absolute neutrophil count &gt; 1000/µL Platelet count &gt; 100'000/µL Renal function : Serum creatinine &lt; 1.5 x ULN Hepatic function : Bilirubin &lt; 1.5x normal Serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level ≤ 2 x ULN No known bleed disorder No known sensitivity allergy NSAIDs No active peptic ulcer disease No active bleeding Secondary Eligibility Histologic diagnosis epithelial ovarian , fallopian tube primary peritoneal cancer confirm frozen section diagnosis debulking surgery Attempted maximal cytoreductive surgery . Patients still eligible whether optimal suboptimally debulked completion surgery . No active bleeding postoperative period Nonepithelial ovarian cancer metastatic cancer another site ovary Borderline ovarian cancer without ascites Uncontrolled unstable medical condition Off study use ketorolac NSAIDs prior study administration within perioperative window ( 7 day surgery time plan study administration ) Active bleed high risk bleed Active therapeutic anticoagulation Known hypersensitivity NSAIDs Chronic acute renal insufficiency define preoperative serum creatinine great 1.5 mg/dL creatinine clearance &lt; 40 ml/min Any comorbid condition ' view attend physician ' render patient high risk ketorolac treatment complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ketorolac</keyword>
	<keyword>GTPase</keyword>
	<keyword>cancer</keyword>
	<keyword>peritoneal</keyword>
	<keyword>fallopian</keyword>
	<keyword>ovarian</keyword>
</DOC>